_
Serono and Israel
Shlomo Maital, "Spelling "Serono" wrong: Why foreign investors have become hesitant about Israel" (22 Sep 2004, Globes Online).
Excerpt: "If someone can’t spell, we say, he writes “Noah” with seven mistakes. How many ways are there to drive away the world’s third largest biotechnology firm, and the largest in Europe, Swiss-based Serono? Israel used them all, and invented new ones. We spelled “Serono” with 10 mistakes. Serono has invested hundreds of millions of dollars in Israel since it first came in 1978. Serono’s global sales were $557 million in the first quarter of this year, and net profit was $106 million, up from $60 million. a year ago. In 2003, it made $390 million in profit on sales of $2 billion. Its success was driven by sales of Rebif, Serono’s multiple sclerosis drug, developed with the help of Israel’s InterPharm. Serono is locked in a fierce battle with American biotech firm Biogen, whose rival MS drug is Avonex, like Rebif an interferon-based drug..." [FullText]
Excerpt: "If someone can’t spell, we say, he writes “Noah” with seven mistakes. How many ways are there to drive away the world’s third largest biotechnology firm, and the largest in Europe, Swiss-based Serono? Israel used them all, and invented new ones. We spelled “Serono” with 10 mistakes. Serono has invested hundreds of millions of dollars in Israel since it first came in 1978. Serono’s global sales were $557 million in the first quarter of this year, and net profit was $106 million, up from $60 million. a year ago. In 2003, it made $390 million in profit on sales of $2 billion. Its success was driven by sales of Rebif, Serono’s multiple sclerosis drug, developed with the help of Israel’s InterPharm. Serono is locked in a fierce battle with American biotech firm Biogen, whose rival MS drug is Avonex, like Rebif an interferon-based drug..." [FullText]
posted by Dr.Koudinov @ 12.11.04
<< Home